20 October 2016

Exercise of options

RNS Number : 6784N
Verona Pharma PLC
28 October 2016


Verona Pharma plc

("Verona Pharma" or the "Company")


Exercise of Options


The Company announces that it has issued 166,667 new ordinary shares in the capital of the Company (the "New Shares") following an exercise of share options by an employee. Application has been made to the London Stock Exchange for the New Shares to be admitted to trading on AIM, with dealings expected to commence on 3 November 2016 ("Admission").


Following Admission, the Company will have a total of 2,566,053,160 Ordinary Shares in issue each carrying one voting right. The Company does not hold any Ordinary Shares in Treasury. This figure of 2,566,053,160 Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.



For further information please contact:

 Verona Pharma plc

Tel: +44 (0)20 3283 4200

 Jan-Anders Karlsson, Chief Executive Officer

 N+1 Singer (Nominated Adviser and Broker)

Tel: +44 (0)20 7496 3000

 Aubrey Powell / Jen Boorer

 FTI Consulting

Tel: +44 (0)20 3727 1000

 Simon Conway/Stephanie Cuthbert/Natalie Garland-Collins

About Verona Pharma plc

Verona Pharma plc is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, such as chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and asthma. 


Verona Pharma's drug candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4, or PDE3 and PDE4, that acts as both a bronchodilator and an anti-inflammatory agent in a single molecule. The Company has successfully completed eight Phase 1 and 2a clinical trials with RPL554 to date, with 299 subjects enrolled. RPL554 has been observed to provide clinically meaningful and statistically significant improvements in lung function as both a single agent and as an add-on therapy with currently marketed bronchodilator drugs. In addition, RPL554 has been observed to shorten the time of onset of bronchodilation when administered as an add-on therapy with currently marketed bronchodilators, and has also shown anti-inflammatory effects. RPL554 has been well tolerated in each of its clinical trials. Verona Pharma also intends to pursue development of RPL554 to address multiple other respiratory diseases, including asthma.

This information is provided by RNS
The company news service from the London Stock Exchange

For further information please contact:


Verona Pharma plc
Jan-Anders Karlsson, CEO
Victoria Stewart, Director of Communications
Tel: +44 (0)20 3283 4200

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance)
Brough Ransom /Mia Gardner (Corporate Broking)
Tel: +44 (0)20 3283 4200



Optimum Strategic Communications
(European Media and Investor enquiries)
Mary Clark, Annemarieke Ezendam
Hollie Vile
Tel: +44 (0) 203 950 9144

Argot Partners (Investor enquiries)
Stephanie Marks
Tel. +1 646 644 9590


Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us